LOGIN  |  REGISTER
Amneal Pharmaceuticals
Assertio

Ontrak Health Announces Breakthrough Increase in Behavioral Health Diagnoses

August 02, 2023 | Last Trade: US$1.44 0.02 -1.37

Diagnoses Confirmed through Innovative Coach-Provider Collaborations

  • Across the company’s book of business 42% of members diagnosed with Substance Use Disorder did not have the diagnosis before enrollment in Ontrak’s WholeHealth+ program
  • Other behavioral health conditions with similar post-enrollment results include 27% for Depression, 27% for Bipolar Disorder, 21% for Anxiety, and 20% for Schizophrenia

HENDERSON, Nev. / Aug 02, 2023 / Business Wire / Ontrak, Inc. (NASDAQ: OTRK), a leading AI-powered and telehealth-enabled healthcare company, has completed a study of thousands of members revealing a substantial increase of new behavioral health diagnoses following enrollment in the WholeHealth+ program. The analysis focused on members’ diagnoses 12 months post-enrollment compared to their diagnoses within the 12 months pre-enrollment, ensuring a comprehensive evaluation of the program's impact on identifying and addressing previously unaddressed behavioral health conditions.

Ontrak’s proprietary AI-imputation algorithm is effectively identifying unaddressed and untreated behavioral health conditions, a key driver of persistent, avoidable healthcare utilization. Ontrak's dedicated care coaches work closely with complex members, providing personalized support to motivate and enhance health literacy, leading to positive behavior changes and increased utilization of the right-sized care, particularly for crucial behavioral health treatments. Members are supported and motivated to engage in consistent care and treatment where new and untreated diagnosis are being uncovered and addressed.

“Accurate and comprehensive diagnosis data provides valuable insights into population health trends, identifies gaps in care, and guides the development of targeted interventions,” said Dr. Judith Feld, Chief Medical Officer at Ontrak. "Our data-driven approach revolutionizes care management and risk adjustment, ensuring that individuals receive comprehensive and well-coordinated support, ultimately benefiting the members and the health plans that serve them."

Ontrak's commitment to updated and new diagnoses mark a significant step forward in healthcare innovation. Embracing this transformative approach, Ontrak empowers health plans to make data-driven decisions, break barriers in mental healthcare, and foster a patient-centered and value-based healthcare system.

About Ontrak, Inc.

Ontrak, Inc. is a leading AI and telehealth-enabled healthcare company, whose mission is to help improve the health and save the lives of as many people as possible. Ontrak identifies, engages, activates, and provides care pathways to treatment for the most vulnerable members of the behavioral health population who would otherwise fall through the cracks of the healthcare system. We engage individuals with anxiety, depression, substance use disorder and chronic disease through personalized care coaching and customized care pathways that help them receive the treatment and advocacy they need, despite the socio-economic, medical and health system barriers that exacerbate the severity of their comorbid illnesses. The company’s integrated intervention platform uses AI, predictive analytics and digital interfaces combined with dozens of care coach engagements to deliver improved member health, better healthcare system utilization, and durable outcomes and savings to healthcare payors.

Learn more at www.ontrakhealth.com.

Stock Quote

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB